ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
2 files

Zeolitic Imidazolate Framework Antibody Conjugates in Bioanalytical Applications

preprint
submitted on 03.10.2020 and posted on 05.10.2020 by Ander Chapartegui Arias, Anna Raysyan, Ana Belenguer, Carsten Jaeger, Teodor Tchipilov, Carsten Prinz, Carlos E. Abad Andrade, Sebastian Beyer, Rudolf. J. Schneider, Franziska Emmerling

Improvements in bioanalytical technologies are driven by evolving threats and challenges to the global community. These challenges include emerging diseases, the need for substance screening and increasing environmental pollution. Here, we present a new bioanalytical concept that employs nanosized Metal-Organic Framework (MOF) particles as labels for antibody-based analytical methods, including enzyme-linked immunosorbent assay (ELISA) and lateral flow immunoassay (LFIA). A strategy for covalently linking antibodies to form stable, colloidal Zeolitic Imidazolate Frameworks (ZIFs) conjugates is described. The proof of principle for their use in LFIA is presented. In particular, ZIF-antibody conjugates displayed excellent behaviour in dispersion and good mobility via lateral flow on a solid substrate while retaining full selectivity of the antibody. Moreover, protein aggregation of the antibodies was prevented, suggesting protection against degradation in an exoskeleton-like manner. Our study could inspire future work to address global bioanalytical and diagnostic challenges.

History

Email Address of Submitting Author

Franziska.Emmerling@bam.de

Institution

Federal Institute for Materials Research and Testing (BAM)

Country

Germany

ORCID For Submitting Author

0000-0001-8528-0301

Declaration of Conflict of Interest

No conflict of interest.

Exports